Carfilzomib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
oprelvekin
Recombinant IL-11
Recombinant IL-11
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
2 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactions
- CarfilzomibSevereDatabaseDDInter
- IfosfamideSevereDatabaseDDInter
Mechanism
Not yet extracted
Indications
stimulate megakaryocyte maturationchemotherapy for nonmyeloid malignancies with severe thrombocytopenia (platelet count <20 × 10^9/L)
Dosing
- Adult
- 25 to 50 μg/kg per day subcutaneously. Administered until the platelet count returns to more than 100 × 10^9/L.
Pharmacokinetics
Half-life
~7 h
Side effects
Common
fluid retentiontachycardiapalpitationedemashortness of breathblurred visioninjection site rasherythemaparesthesias
Drug interactions
Ifosfamide
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Ask House about oprelvekin
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team